The first dose of the BNT162 vaccine program began in Germany last week, according to a corporate statement. The testing phase aims to recruit up to 360 patients, aged 18 to 55. Once the younger organization has produced false tests of protection and immunogenicity, tests will begin in older adults or seniors ages 65 to 85.
CLICK HERE FOR FULL COVERAGE OF CORONAVIRUS
“With our unique and physically powerful clinical curriculum underway, starting in Europe and now in the United States, we look forward to moving forward with our BioNTech partners and the regulatory government to deliver an effective vaccine to the patients who want it most,” said Albert Bourla, Ceo and Ceo of Pfizer , in the press release.
Participant sites come with NYU Grossman School of Medicine and the University of Maryland School of Medicine.
POSSIBLE CORONAVIRUS VACCINE ENTERED HUMAN TESTING
The University of Rochester/Rochester Regional Health Medical Center and Cincinnati Children’s Hospital Medical Center will begin enrolling “soon,” according to the company’s statement.
The progression program consists of 4 candidate vaccines, another mixture of a messenger RNA format (MRNA), vital in protein synthesis, and a target antigen.
The trial will compare the other candidate vaccines with the effects of the safest and most effective vaccine.
Anticipating success, Pfizer and BioNTech are expanding production for global sourcing, according to the company’s statement. The program is expected to produce millions of doses of vaccines by 2020, with millions of production the following year.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Determined manufacturing sites to date include Pfizer-owned sites in Massachusetts, Michigan and Missouri, as well as Puurs, Belgium and others in the future. BioNTech will contribute to production capacity through sites in Mainz and Idar-Oberstein, Germany.
According to the World Health Organization, 102 vaccines opposed to COVID-19 were in progress as of April 30. Eight of the applicants were approved for clinical trials.